Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo is a research paper published in Cancer Cell (2015). On theSindex it has a DataRank of 0.902. It has been cited 408 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.902
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health (NIH) grant R01
Grant: 1R01CA160467
NIH T32
Grant: HD007505
NIH T32
Grant: GM007315
Leukemia and Lymphoma Society (LLS) TRP grant
Grant: 6116-12
LLS Scholar
Grant: 1215-14
American Cancer Society
Grant: RSG-11-082-01-DMC
American Cancer Society
Grant: RSG-13-130-01-CDD
USA Department of Energy, Office of Science, Office of Basic Energy Sciences
Grant: DE-AC02-06CH11357
Michigan Technology Tri-Corridor
Grant: 085P1000817
NCI NIH HHS
Grant: R01 CA160467
NICHD NIH HHS
Grant: T32 HD007505
NCI NIH HHS
Grant: R01 CA151425
NIAID NIH HHS
Grant: R01 AI091627
NIGMS NIH HHS
Grant: T32 GM007315
NCI NIH HHS
Grant: P30 CA046592
Michigan Economic Development Corporation
Department of Pathology, University of Michigan
LLS Therapy Acceleration Program
FWCI
14.21
Citation Percentile
1.0%
Influential Citations
25
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1
Additional file 1 of A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1
Additional file 1 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 1 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 2 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 2 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 3 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 3 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 4 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 4 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 5 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 5 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 6 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 6 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 7 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 7 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 8 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 8 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 9 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
Additional file 9 of Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML